Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA

July 29, 2024

Richland WA, July 29, 2024 (GLOBE NEWSWIRE) — Vivos Inc. (OTCQB:RDGL), Vivos Inc. Provides IDE Submission Status Update

Related news for (RDGL)

Vivos Inc. Certifies University of Florida Veterinary Hospital for IsoPet® Precision Radionuclide Therapy™
Vivos Inc. Achieves Record Growth in IsoPet® Animal Cancer Treatments in Q1 2025
Vivos Inc. Reports Encouraging Human Clinical Trial Results and Announces Expansion Plans
Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide
Vivos Inc. Announces Launch of Groundbreaking RadioGel® Precision Radionuclide Therapy™ Human Clinical Trial

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.

Vivos Inc. Provides IDE Submission Status Update – Conversion to Pre-Sub Filing Accepted by the FDA

Related news for (RDGL)

Follow Us on Social Media

Sign Up for Our Newsletter

Related news for (RDGL)

Midday Market Dispatch- From Eco‑Boards to AI Batteries

Market Spotlight: APLD Powers AI, KDK Rolls Out, FICO Reinvents Scoring—And VENU Amplifies the Concert Economy

Kraig Labs Unlocks Spider Silk at Scale, Solving a Historical Problem for Nature’s Toughest Fiber

VENU Leads the Intimate Concert Trend with Boutique Venue Solutions

Palisade’s Blockbuster Raise and Kraig’s Next-Gen Textiles Light Up the Morning

Follow Us on Social Media

Sign Up for Our Newsletter